Heterogeneity of cell therapy products

Wolmarans, Elize; Mellet, Juanita; Ambele, Melvin Anyasi; Durandt, Chrisna; Pepper, Michael Sean

dc.contributor.author	Wolmarans, Elize
dc.contributor.author	Mellet, Juanita
dc.contributor.author	Ambele, Melvin Anyasi
dc.contributor.author	Durandt, Chrisna
dc.contributor.author	Pepper, Michael Sean
dc.date.accessioned	2020-05-27T10:07:51Z
dc.date.available	2020-05-27T10:07:51Z
dc.date.issued	2019-08
dc.description.abstract	Cellular therapy has become a billion-dollar industry and is set to become one of the therapeutic pillars of healthcare in the 21st century. Adult stem cells, which include haematopoietic stem and progenitor cells (HSPCs) and mesenchymal stromal/stem cells (MSCs), is one of the major cell types currently under investigation for use in cell therapy. This review focuses on HSPCs and MSCs and discusses their heterogeneous nature and the problems faced in expanding these cells to therapeutic numbers for use in clinical applications.	en_ZA
dc.description.department	Immunology	en_ZA
dc.description.librarian	pm2020	en_ZA
dc.description.uri	http://www.samj.org.za	en_ZA
dc.identifier.citation	Wolmarans, E., Mellet, J., Ambele, M A., Durandt, C. & Pepper, M S. 2019, 'Heterogeneity of cell therapy products', South African Medical Journal, vol. 109, no. 8, pp. S25-S29.	en_ZA
dc.identifier.issn	0256-9574 (print)
dc.identifier.issn	2078-5135 (online)
dc.identifier.other	10.7196/SAMJ.2019.v3109i8b.13822
dc.identifier.uri	http://hdl.handle.net/2263/74752
dc.language.iso	en	en_ZA
dc.publisher	Health and Medical Publishing Group	en_ZA
dc.rights	© 2019, South African Medical Association. This article is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0).	en_ZA
dc.subject	Cellular therapy	en_ZA
dc.subject	Adult stem cells	en_ZA
dc.subject	Haematopoietic stem and progenitor cells (HSPCs)	en_ZA
dc.subject	Mesenchymal stromal/stem cells (MSCs)	en_ZA
dc.title	Heterogeneity of cell therapy products	en_ZA
dc.type	Article	en_ZA